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Bile acid binding to sevelamer HCl. [10, 11], it is hypothesized that the cholesterol lowering
Background. Clinical studies have shown sevelamer HCl effects observed for sevelamer involve the binding of
(Renagel) to be effective for the reduction of serum phos- bile acids in a manner similar to the commercial bile acidphate in hemodialysis patients. These studies also consistently
sequestrants cholestyramine, colestipol and colesevelam.have demonstrated a significant reduction of low-density lipo-
Bile acid sequestrants function by binding bile acids inprotein (LDL) cholesterol following treatment with sevelamer.
Methods. Equilibrium binding of bile acids and oleic acid the gut and carrying them through the gastrointestinal
was determined by incubating sevelamer with ligand containing tract, resulting in an increase in bile acid excretion in the
buffer. Aliquots of the solution were filtered and the free ligand feces. This removal of bile acids from the entero-hepaticconcentrations quantitated by high-pressure liquid chromatog-
circulation results in an up-regulation of the hepatic en-raphy (HPLC). Flow kinetics were determined using a cylindri-
zyme cholesterol 7-hydroxylase, which catalyzes thecal flow cell containing trapped sevelamer. Bile acid and oleic
acid were pumped through the stirred cell in a manner designed rate limiting step in the synthesis of bile acids from he-
to mimic the in vivo situation. Binding was monitored by HPLC. patic cholesterol. The resulting depletion of liver choles-
Results. Sevelamer binds bile acids cooperatively and with terol is accompanied by an increase in hepatic LDL re-high capacity. At low binding densities, the presence of the more
ceptor activity, thereby enhancing LDL clearance fromhydrophobic bile acids enhances the binding of the less hydro-
circulation. In order to test the hypothesis that sevelamerphobic bile acids, and the presence of oleic acid enhances the
binding of all bile acids. At saturating oleic acid concentrations, can function as a bile acid sequestrant, we performed
the bile acid binding capacity of sevelamer is reduced by only a equilibrium and flow kinetic studies of the binding of bile
factor of two. Moreover, the presence of oleic acid dramatically acids to sevelamer. We find that sevelamer has excellentdiminishes the release rate of bile acids from sevelamer.
capacity for binding bile acids. Moreover, the coopera-Conclusions. The favorable bile acid binding characteristics
of sevelamer provide a compelling explanation for its ability to tive binding of bile acids and of fatty acids, under simu-
lower LDL cholesterol in hemodialysis patients and in healthy lated physiological conditions, can result in (1) substan-
volunteers. tial total binding of bile acids, (2) an enhanced affinity
for less hydrophobic bile acids, and (3) very slow bile
acid release kinetics. These results support the hypothe-
Sevelamer HCl, marketed under the trade name Rena- sis that the reductions in LDL cholesterol observed in
gel (Genzyme Corp., Cambridge, MA, USA), is a cross- clinical trials with sevelamer reflect the property of this
linked, hydrophilic, water-swellable, cationic hydrogel cationic hydrogel to cooperatively bind bile acids and
that has shown efficacy in reducing serum phosphate fatty acids.
levels in hemodialysis patients [1–4]. Chemically, seve-
lamer is a cross-linked polyallylamine polymer (Fig. 1).
METHODSClinical studies in hemodialysis patients consistently
have shown that, in addition to its primary function as Equilibrium binding: Experimental
a phosphate sequestrant, sevelamer also significantly re- For binding isotherms obtained in the absence of ole-
duces low-density lipoprotein (LDL) cholesterol [2, 3, ate, the binding buffer contained 75 mmol/L sodium bi-
5–9]. A reduction in LDL cholesterol also was observed carbonate, 60 mmol/L sodium chloride, 8 mmol/L potas-
in healthy volunteers who were fed a controlled phos- sium chloride, 3 mmol/L sodium phosphate, 2 mmol/L
phate diet [1]. Since sevelamer shares the non-absorbed magnesium chloride, and 2.5 mmol/L calcium chloride.
cationic character of commercial bile acid sequestrants The pH of the solution was adjusted into the range of
6.8 to 7.2 using 1 N HCl.
Bile acid stock solution contained 15 mmol/L bile acid.Key words: end-stage renal disease, cholesterol, atherosclerosis, vascu-
lar disease, lipid metabolism, hemodialysis, bile acid sequestrants. For the individual bile acid isotherms, this solution con-
sisted of a single bile acid. For the mixed bile acid iso- 2002 by the International Society of Nephrology
611
Braunlin et al: Bile acid binding to sevelamer612
Fig. 1. Structure of sevelamer HCl. a and b
denote the number of primary amine groups;
c is the number of cross linking groups; n is
the fraction of protonated amines; and m is the
large number to indicate the polymer network.
therms, this solution consisted of 7.5 mmol/L cholyl gly- Binding experiments were performed in the following
manner: 30  3 mg of polymer was placed in 50 mLcine (GC), 3 mmol/L cholyl taurine (TC), 1.5 mmol/L
chendeoxycholyl glycine (GCDC), 1.5 mmol/L deoxy- flasks, to which 30 mL of buffer solution containing the
appropriate amounts of bile acid, CHAPS and OA werecholyl glycine (GDC), 0.75 mmol/L chendeoxycholyl tau-
rine (TCDC), and 0.75 mmol/L deoxycholyl taurine added (except for the CHAPS alone experiment, for
which 15 mL was used). The 20% variation in polymer(TDC), to give final mole percents of 50:20:10:10:5:5 for
GC:TC:GCDC:GDC:TCDC:TDC. This ratio was cho- weight is unlikely to be of significant consequence since
the bound ligand was normalized against the polymersen to mimic the bile acid distribution found in humans.
For binding isotherms performed in the presence of weight, and the free ligand was determined directly by
HPLC. The flasks were then vortexed for approximatelyoleic acid, the binding buffer consisted of 100 mmol/L
BES (N,N-bis [2-hydroxyethyl]-2-aminoethanesulfonic 30 seconds and shaken for at least 18 hours at 37C and
355 rpm to produce a continuous uniform mixture ofacid), 160 mmol/L NaCl and 20 mmol/L CHAPS {3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane sulfo- polymer and bile acid solution. This time frame seemed
sufficient, since Benson and colleagues demonstratednate hydrate}. The addition of CHAPS, a zwitterionic
bile acid derivative, ensured the aqueous solubility of that bile acids (GC, TC, GCDC, TCDC, GDC and TDC)
equilibrate with cholestyramine within a one-hour timeoleic acid. This buffer was adjusted to pH 6.8 with NaOH.
The sodium salt of oleic acid was used to prepare 10 period under conditions similar to those reported here
[12]. The pH was adjusted to the range of 6.8 to 7.2 usingmmol/L solution of oleic acid (OA) by mixing it in BES
buffer containing CHAPS and sonicating for 10 minutes 1 N HCl and the tube was shaken vigorously at 37C for
an additional two to three hours. Approximately 2 mLto dissolve the OA.
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Table 1. Time course of the flow kinetics experimentof solution was filtered using a 0.45 m filter device and
used for HPLC quantitation. Stage Mobile phasea Time minutes
The free bile acid concentrations were determined by 1 Bile acids  Oleic acid 30
HPLC. The HPLC system was an HP 1100 (Hewlett- 2 Bile acids 30
3 Physiological buffer 90Packard Instruments, Palo Alto, CA, USA) with a Sedex 55
4 Flushing solution 60evaporative light scattering detector (Sedere, Alfortville,
a For the experiments performed in the absence of oleic acid, stages 2 and 3France). The flow rate was 1.00 mL/min with a column
were combined into a single 60-minute association phase
temperature of 50C and an injection volume of 25 L.
The detector temperature was 40C with a nitrogen pres-
sure of 1.8 bar. Standard solutions were used to convert
detector response into bile acid concentrations. About (mmoles per g of polymer) and (Smax) is the total density
ten standard bile acid and oleic acid solutions were pre- of sites (mmoles per g of polymer); (L) is the free ligand
pared by half dilution of the stock 15 mmol/L solution. concentration in mmol/L. One physical interpretation of
Data points (peak height vs. concentration) were fitted the Hill equation for the current situation is as follows:
with a straight line passing through the coordinate origin. Bile acids are concentrated within the anionic polymer
Bound ligand, r (mmoles bound ligand per gram of domain, where they associate as aggregates of size n.
polymer) was calculated according to the following for- The results of these fittings are given in Table 1, and
mula for each individual ligand: will be discussed later (Discussion section).
r 
(Li)  (L)
Wp
* Vt (Eq. 1) Flow kinetics: Experimental
In the flow experiment, the physiological buffer con-
where [Li] is the initial concentration of ligand (mmol/L), sisted of 25 mmol/L NaHCO3, 110 mmol/L NaCl, 8 mmol/L
Vt is the liquid volume in the flask (30 mL), (L) is the KCl, 3 mmol/L NaH2PO4. The pH of the solution was ad-
measured concentration of ligand (mmol/L), and Wp is justed into the range of 6.95 to 7.05 using 1 N HCl. The
the dry weight of the polymer (corrected for water loss buffer solution was filtered through a 0.45m Nylon filter.
on drying). The methanol/water flushing solvent consisted of a
For the measurement of CHAPS alone, an Alltima 60/40 (vol:vol) mixture of methanol and an aqueous,
C18 3 m column (Alltech, Deerfield, IL, USA) was used. 30 mmol/L ammonium acetate solution (pH 5.3). The
The system was run isocratically with the mobile phase bile acid solution was 10.5 mmol/L GC, and 4.5 mmol/L
consisting of approximately 15 mmol/L ammonium ace- GDC. To this 15 mmol/L bile acid solution was added
tate, 60% methanol, and 3% 1-propanol adjusted to pH 15 mmol/L oleic acid to give the oleic acid mobile phase.
5.3 with acetic acid. The presence of this amount of bile acid sufficed to
For the separation of the bile acids and CHAPS, a solubilize the oleic acid.
Platinum 100A 3-m column (Alltech) was used. The
The cylindrical flow cell had a total volume of aboutsystem was run isocratically with the same mobile phase
1.5 mL. Both ends of the cell were stoppered with 70 mas before except with a pH of 5.8. The higher pH value
frits. A 25m Teflonmembrane (DuPont, Wilmington,was needed to separate the CHAPS peak from the GDC
DE, USA) was clamped to the outlet side of the cell. Apeak, which eluted at a similar time.
stirring bar in the middle of the cell was used to ensureFor the separation of bile acids, CHAPS, and OA, a
good mixing during the time-course of the flow experi-Platinum EPS 100A 3 m column (Alltech) was used.
ment. The dry weight of the polymer in the cell variedA gradient was run with mobile phase A being the mobile
between 14.7 and 15.3 mg.phase as before (pH 5.8) and mobile phase B being 100%
The polymers were swollen in physiological buffer formethanol. Mobile phase A (100%) was run for 3.5 min-
more than one hour before the experiment. During theutes. From 3.5 to 4.0 minutes a gradient up to 95% mobile
experiment, the cells were immersed in a water bath atphase B was run. This was held constant until 7.0 minutes,
37C, and positioned on top of magnetic stirrers. Priorat which time a gradient returned the mobile phase to
to starting the experiment, physiological buffer was al-100% A at 7.1 minutes. The total run time was 10 min-
lowed to flow through the cell for 20 minutes.utes. The gradient with a higher amount of methanol
Each experiment was separated into four continuouswas needed to elute the oleic acid from the column.
stages, as summarized in Table 1. For the experiments
Equilibrium binding: Data analysis performed in the absence of oleic acid, stages 2 and 3
Equilibrium isotherms were fitted to the Hill equation: were combined into a single 60-minute association phase.
The mobile phases were controlled by HPLC. The
r  (Smax)
Kn (L)n
1  Kn (L)n
(Eq. 2) sample collection was controlled by an automated liquid
handler (Gilson, Lewis Center, OH, USA). Sample col-
lection started from stage 1. The collection interval forIn this equation, r is the density of bound sites
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the first 120 minutes was set at 2 minutes per vial. For VF, volume of the reactor cell (1.5 mL); C, the instanta-
the final 72 minutes, this interval was 6 minutes per vial. neous concentration of bile acid within the cell.
For experiments run in the absence of oleic acid, analy- The master equation is that of mass balance:
ses were performed directly from the automated liquid
NB  NIN  NOUT  VF * C (Eq. 3)handler. Experiments run in the presence of oleic acid
were analyzed by direct injection from the HPLC. where NIN   t0 dNIN  C0 · F · t during the association
The mobile phase for the analysis was a 60/40 (vol:vol) part of the curve, and where NIN  N0IN   t0 dNIN   tA0
mixture of methanol and 15 mmol/L aqueous solution dNIN  Co · F · tA during the dissociation part of the curve.
of ammonium acetate. For the analysis, we used a 33 mm The Ci	 is measured in this experiment, and the
C18 reverse phase column from Alltech with an inner concentration averaged from ti1 to ti (ti  ti1  
ti).
diameter of 7 mm. The temperature of the column was By summation we obtain:
kept at 47C. The flow rate of the mobile phase was
1.0 mL/min for internal HPLC injection, and 2.0 mL/ NOUT  
Z
i1
F * 
ti * Ci (Eq. 4)
min for injection through the auto sampler. The detector
was an evaporative light scattering detector, Sedex 55. where Z is the total number of time intervals. Note that
For this detector, the temperature was set at 40C, the FCdt  dNOUT can be written in differential form as:
pressure at 1.7 bar, the manual gain at 7.0.
The injection volume was selected to maximize the C 
1
F 
dNOUT
dt  (Eq. 5)oleic acid peak without saturating the detector. It was
about 6 L for internal HPLC injection, 25 L for injec-
Since we knew NOUT versus t at intervals of 
t, C(t) wastion through the auto sampler.
obtained by differentiation of this curve. Substitution ofRetention times were measured at 2.5 minutes, 3.25
C into equation 3 gave NB versus t. The only unknownminutes and 5.2 minutes for glycocholic acid (GC), glyco-
at this point was VF. Since the polymer was expected todeoxycholic acid (GDC), and oleic acid (OA), respec-
take up a negligible physical volume in the cell, thistively. The overall time window was about seven minutes
quantity should be close to the physical cell volume. VFor less.
was obtained by fitting the concentration versus timeStandard solutions were used to convert detector re-
curve obtained for the blank (which showed an exponen-sponse into bile acid concentrations. About ten standard
bile acid and oleic acid solutions were prepared by half tial time constant for mixing that was equal to
F
VF
), and
dilution of the stock 15 mmol/L solution. Data points
found values in the range of 1.3 to 1.5 mL.(voltage vs. concentration) were fitted with a straight line
passing through the coordinate origin.
RESULTSFlow kinetics: Data analysis
Equilibrium bindingIf tA is the time during which the ligand flows through
The equilibrium binding of individual bile acids tothe cell (the association time), under our experimental
sevelamer was examined in physiological buffer at 37C.conditions, tA  60 minutes for all bile acids, and 30
As observed in our earlier study for bile acid binding tominutes for oleic acid. During this time a concentration
other bile acid sequestrants [13], the binding behaviorsC0 (mmol/L) of ligand flows into the stirred cell at a rate
of GCDC and GDC to sevelamer are indistinguishable,F (fixed at 0.25 mL/min). In our experiments, C0 is fixed
as are the binding behaviors of TCDC and TDC (dataat 10.5 mmol/L GC, 4.5 mmol/L GDC, and 15 mmol/L
not shown). Fits to equation 2 of the binding data foroleic acid. This association is followed by tD minutes of
GC, TC, TCDC and GCDC binding to sevelamer aredissociation (tD  90 min for bile acids, and 120 min for
shown in Figure 2 and are tabulated in Table 2. Alsooleic acid). After a total time of 150 minutes, a solution
shown in Table 2 are the dissociation constants Kd of MeOH/NH4OAc is pumped through for 30 minutes
K1a , which define the concentration midpoints of the(150 to 180 min) to displace any remaining ligand. The
binding curves. The clearly sigmoidal plots of bindingoutput is collected as fractions. Each fraction is collected
density versus free bile acid concentration [(LB) vs. (L)]over a time 
ti, which for our experiments is either 2 or
in equation were best fitted using Hill parameters n of6 minutes. The mass of polymer within the cell is fixed
about 4. For sevelamer, as we have seen for other bileat 15 mg. The following parameters are defined as: NB,
acid sequestrants [13], the order of bile acid bindingtotal number of micromoles of bile acid bound within
strength was TDC  TCDC 	 GDC  GCDC 	TC 	the cell; NIN, total number of micromoles of bile acid
GC (Table 2). On the basis of saturation capacity (Smax)that have flowed into the cell; NOUT, total number of
micromoles of bile acid that have flowed out of the cell; in mmoles bound per gram of polymer, the bile acid
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Fig. 3. Binding of a physiological mixture of bile acids to sevelamerFig. 2. Binding of cholyl glycine (GC; ), cholyl taurine (TC; ),
in physiological buffer. In this experiment, the ratio of GC:TC:chendeoxycholyl glycine (GCDC; ), and deoxycholyl glycine (GDC;
GCDC:GDC:TCDC:TDC was 10:4:2:2:1:1. Symbols are: () total bile) to sevelamer HCl. The curves are the best fits to the data to the
acid; () GC, () TC; () GCDC  GDC; () TCDC  TDC. Theparameters summarized in Table 2.
curves are spline fits, and are presented as a visualization aid.
Table 2. Fitting parameters obtained for the binding of individual
bile acids to sevelamer HCl
Bile acid Ka mmol/L1 N a Smax mmol/g Kd mmol/L
GC 0.160.02 4 5.10.8 6.3
TC 0.200.02 4 5.10.6 5.0
GCDC  GDC 0.870.03 4 7.50..2 1.1
TCDC  TDC 2.00.3 4 7.40.7 0.5
a N was fixed at 4
binding capacity of sevelamer met or exceeded that of
conventional bile acid sequestrants [13].
Upon comparing Figures 2 and 3, the binding of in-
dividual bile acids to sevelamer was quite different from
the binding of bile acids in mixed bile acid solution.
Whereas the individual bile acids showed distinct concen- Fig. 4. Binding of a physiological mixture of bile acids to sevelamer
in physiological buffer (conditions as in Fig. 3), plotted as % boundtration midpoints (Kd) ranging from about 0.5 mmol/L to
versus free bile acid concentration. Symbols are: () GC, () TC; ()about 6 mmol/L when monitored in isolation (Fig. 2 and
GCDC  GDC; () TCDC  TDC.
Table 2), when monitored in a mixture, the concentration
midpoints for the binding of the individual bile acids
were all around 1 mmol/L (Fig. 3). This point is made
more clearly in Figure 4 where the data of Figure 3 were However, as a bile acid mixture was added to sevelamer
containing 20 mmol/L CHAPS, binding of CHAPS in-replotted as the percent of a particular bile acid bound
as a function of the free bile acid concentration. Note creased with bile acid binding and then leveled off and
decreased slightly at higher bile acid concentrations.also that in both Figures 3 and 4 the data were plotted
against the free bile acid concentration, which was the Note that the total CHAPS concentration was constant
at 20 mmol/L, whereas the total bile acid concentrationsum of the free (that is, unbound) bile acid concentra-
tions of each of the individual bile acids. This result varied from 0 to 15 mmol/L. Hence, even in the presence
of fatty acids, the bile acids bound with much greaterdemonstrates that the binding of the more hydrophobic
dihydroxy bile acids (GDC, GCDC, TDC and TCDC) affinity to sevelamer than did CHAPS.
The rationale for using CHAPS was to solubilize oleiccooperatively enhances the binding of the more hydro-
philic trihydroxy bile acids (GC and TC). acid in aqueous solution so that the effect of oleic acid
on bile acid binding could be monitored. As shown inThis cooperative effect is even more dramatic for the
case of the binding of CHAPS, a zwitterionic bile acid Figure 6, the presence of oleic acid dramatically en-
hanced bile acid binding at lower binding densities with-analog. As shown in Figure 5, in the absence of added
bile acid, no binding of CHAPS occurred to sevelamer. out greatly reducing the total bile acid binding capacity.
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Fig. 5. Binding of a physiological mixture of bile acids to sevelamer
in 100 mmol/L BES in the presence of 20 mmol/L CHAPS. As before,
the ratio of GC:TC:GCDC:GDC:TCDC:TDC was 10:4:2:2:1:1. Symbols
are: () total bile acid bound; () CHAPS bound; () CHAPS  bile
acid bound. The curves are spline fits, and are presented as a visualiza-
tion aid.
Fig. 6. Binding of a physiological mixture of bile acids to sevelamer
in 100 mmol/L BES in the presence of 20 mmol/L CHAPS and 10Flow kinetics: Fixed bile acids, no fatty acid
mmol/L oleic acid. As before, the ratio of GC:TC:GCDC:GDC:TCDC:
Flow cell studies were performed to examine the net TDC was 10:4:2:2:1:1. Symbols are: () total bile acid bound; () oleic
acid bound; () oleic acid plus bile acid bound; () CHAPS bound;association and dissociation rates of bile acids under
() TC bound; () GC bound; () TDC TCDC bound; () GDCconditions designed to mimic those encountered by the
GCDC bound. CHAPS was added to ensure the aqueous solubility of
polymers as they traverse the gastrointestinal tract. The oleic acid. The curves are spline fits, and are presented as a visualiza-
tion aid.chosen conditions were based on experimental results
of the concentrations of bile salts and fatty acids in the
gut [14–16]. Clearly, gastrointestinal transit times were
highly variable in normal humans, and concentrations
of fatty acid, bile acid association kinetics were rapid forof fatty acids and bile salts may have varied with diet.
both GC and GDC binding to sevelamer. Dissociation ofThe chosen conditions nonetheless allowed us to exam-
GC also was rapid, so that by the end of the dissociationine trends in behavior, even though we did not expect
period, very little GC remained bound to sevelamer.them to be quantitatively predictive.
During the association part of this experiment, a solu- Flow kinetics: Mixed bile acids in the presence
tion of mixed bile acid (15 mmol/L total bile acid, 70% of fatty acid
GC, 30% GDC) in physiological buffer was pumped at
To more closely mimic in vivo conditions, flow cell0.25 mL/min through a 1.3 mL volume mixing chamber
studies were performed to examine the effect of oleic acidcontaining either buffer plus polymer gel or buffer alone
on the kinetics of bile acid binding. The above experimen-(blank). The chamber was stirred and maintained at
tal methodology was modified in the following manner:37C. Association occurred during the first 60 minutes.
During the association part of the experiment, a solu-After 60 minutes, the dissociation phase began. At the
tion of mixed bile acid (15 mmol/L total bile acid, 70%start of this phase, bile acid flow was stopped and buffer
GC, 30% GDC) in physiological buffer was pumped atflow was started. Buffer was pumped through the cell
0.25 mL/min through a 1.3 mL volume mixing chamberfor 90 minutes. At 60 90 150 minutes, the remaining
containing either buffer plus sevelamer or buffer alonebound bile acid was removed from the polymer by flush-
(blank). The chamber was stirred, and maintained ating the cell with methanol/ammonium acetate. Hence,
37C. During the first 30 minutes, association occurredat 20 minutes we were in the middle of the association
in the presence of 15 mmol/L OA. During the next 30phase. At 60 minutes, the association phase was com-
minutes, the cell was flushed with 15 mmol/L bile acidpleted, and the dissociation phase began. At 150 minutes,
alone. After 60 minutes, the dissociation phase began.mass balance was verified by displacing bound bile acids
At the start of this phase, bile acid flow was stopped, and(displacement phase). Results of these experiments are
buffer flow was started. Buffer was pumped through theshown in Figure 7, for selected time points.
These experiments demonstrated that, in the absence cell for 90 minutes. At 60  90  150 minutes, the
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Fig. 7. Time course of bile acid binding and
oleic acid binding to sevelamer HCl in a stirred
flow experiment. The ‘minus’ plots show bind-
ing in the absence of oleic acid, whereas the
‘plus’ plots show binding in the presence of
oleic acid. In this experiment the input ratio
of GC:GDC was 70:30. During the first 30 min-
utes, a solution containing either 15 mmol/L
total bile acid (minus) or 15 mmol/L bile acid
plus 15 mmol/L oleic acid (plus) flowed into
the cell. From 30 to 60 minutes, in both cases,
15 mmol/L bile acid—but not oleic acid—
flowed into the cell. From 60 to 150 minutes,
the cell was flushed with buffer. In order to
verify mass balance, the cell was then flushed
with methanol/sodium acetate from 150 to 240
minutes, in order to displace residual bound
bile acid. The length of the black bars gives
the amount of GC bound, and the length of
the light gray bars gives the amount of GDC
bound. The total bound bile acid is equal to
the sum of these two lengths. The dark gray
bars correspond to the amount of oleic acid
bound. Hence, the total ligand bound (bile
acid plus oleic acid) is equal to the sum of all
three lengths.
remaining bound ligand (bile acid  oleic acid) was re- unit of about 4 provides a good fit to the data. The size
of this cooperative unit is comparable to that of a typicalmoved from the polymer by flushing the cell with metha-
nol/ammonium acetate. bile acid micelle [17]. Hence, the picture arises of the
association and cooperative binding of bile acid aggre-The results of this experiment are shown also in
Figure 7. It is clear from comparing the curves obtained gates within the polymer domain. As illustrated in Fig-
ure 2, at between 5 and 8 mmole bile acid per gram ofin the presence of OA to those in the absence of OA
that OA competed for binding to sevelamer during the polymer, the binding capacity of sevelamer for bile acids
is quite high. For comparison, the intrinsic binding capac-association phase, and thus modestly reduced the total
amount of bile acid bound during association. The most ity of cholestyramine has been estimated at about 3 to
6 mmoles per gram [18–20]. However, the total bindingdramatic effect, however, was that the otherwise rapid
dissociation of GC was significantly retarded by the pres- capacity is only one of several parameters that may ulti-
mately determine the biological efficacy of a bile acidence of oleic acid. As a consequence of this effect, by
the end of the dissociation phase there was a significant sequestrant. In fact, it has been argued that the efficacy
of a bile acid sequestrant may reflect in large part itsamount of GC bound in the presence of oleic acid, but
no measurable GC bound in the absence of oleic acid. ability to bind the less hydrophobic bile salts, in particu-
lar GC [12, 21, 23]. This hypothesis is supported by theAs a consequence of the enhanced binding of GC, the
total amount of bile acid bound at the end of the dissocia- clinical data of Dam et al [23]. These data showed that,
for six patients treated with 400 mg/kg per day of cholest-tion phase also was significantly greater in the presence
of oleic acid than in the absence. yramine, the molar percentage of GC to total bile acid
in human bile increased greatly in all cases. On average,
this percentage increased from 27 to 55% after three
DISCUSSION weeks of treatment, and further to 61% after six weeks
Sevelamer binds bile acids cooperatively and of treatment. Furthermore, for these six patients, the
with a high capacity average ratio of trihydroxy to dihydroxy bile acid in-
creased from 0.63 to 1.6 after three weeks of treatment,The sigmoidal binding curves shown in Figure 2 dem-
and to 2.1 after six weeks of treatment. If binding trihy-onstrate that sevelamer binds bile acids cooperatively.
When fitted to the Hill model (equation 2), a cooperative droxy bile acids is important, then there are distinct ad-
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vantages to a hydrophilic cooperatively-binding polymer also show a similar reduction in clinical efficacy over
time as is seen for cholestyramine.such as sevelamer, compared to a more hydrophobic se-
questrant such as cholestyramine. A comparison of Fig-
Fatty acids slow the release of GC from sevelamerures 2, 3 and 4 shows that, although the intrinsic binding
Nonetheless, it should be recognized that in vivo, GCaffinity of sevelamer for GC is rather weak, the presence
is likely to be released from a polymer that has beenof even trace amounts of more hydrophobic (dihydroxy)
pre-loaded with fatty acids. As also shown in Figure 7,bile acids can dramatically enhance GC binding at low
under such conditions in vitro, GC release from seve-binding densities. The picture that emerges is of coopera-
lamer is dramatically slowed. In contrast to the situationtive binding of mixed bile acid micelles. Even more dra-
in the absence of fatty acid, where no residual GC bind-matic is the ability of saturating quantities of fatty acid
ing could be discerned following the dissociation period,to facilitate the binding of all bile acids, including GC
in the presence of oleic acid, GC binding is comparable(Fig. 6). In contrast, fatty acids compete with bile acids
to GDC binding. Hence, the data suggest the intriguingfor binding to more conventional bile acid sequestrants,
hypothesis that the presence of fatty acid can actuallyand may play a dominant role in limiting the efficacy of
enhance the ability of sevelamer to hold on to trihydroxycholestyramine [24].
bile acids in vivo as well as in vitro.Other factors present in the GI tract also may influence
bile acid binding to sevelamer. For example, phosphoti- Conclusions
dylcholine could compete with bile acids for binding.
Equilibrium binding properties. As for previously stud-Variations from neutral pH are possible. However, since
ied bile acid sequestrants, the binding strength of theactive transport of bile acids occurs at the terminal ileum,
naturally occurring bile acids to sevelamer follows thepH variations would have to occur prior to passage into
order: TCDC  TDC 	 GCDC  GDC 		 TC 	 GC.the colon from the terminal ileum in order to influence
This ordering reflects a dominant preference of all se-significantly the efficacy of sevelamer as a bile acid se-
questrants for more hydrophobic bile acids (dihydroxyquestrant. In any case, the effective pKa of sevelamer
vs. trihydroxy), and a minor but still significant prefer-should be about 9.5, based on unreported measurements
ence for taurine-conjugated bile acids compared to gly-that we have performed on a closely related cross-linked
cine-conjugate bile acids. However, for sevelamer, thispolyallylamine polymer, and even at pH 8.0, which could
preference is essentially nullified in mixed bile salt solu-occur in the distal colon [25], about 75% of the amines
tion due to the cooperative nature of bile acid binding.on this polymer should be fully protonated.
Cooperative interactions. Sevelamer shows coopera-
tive binding isotherms that are well fitted by equation 2In the absence of fatty acids, sevelamer
with N  4. In mixed solutions of bile acids, at lowreleases GC very rapidly
binding densities, the presence of more hydrophobic bile
As Benson and colleagues have shown, trihydroxy bile acids facilitates the binding of more hydrophilic bile
acids are released rapidly from cholestyramine on the acids. Most dramatically, the presence of saturating
time-scale of transit through the gastrointestinal tract [12]. quantities of oleic acid strongly facilitates the binding
Combining this observation with the intrinsic poor affin- of bile acids at low binding densities, without greatly
ity of cholestyramine for trihydroxy bile acids provides diminishing total binding capacity.
a plausible hypothesis for the relatively poor clinical po- Bile acid binding dynamics. In the absence of oleic
tency of this bile acid sequestrant. As clinical studies acid, sevelamer binds bile acids rapidly, and releases GC
have shown, prolonged treatment with cholestyramine very rapidly. In contrast, flow measurements performed
would over time result in a perturbation of the biliary in the presence of oleic acid show a marked decrease in
bile acid pool toward one richer in trihydroxy bile salts, the GC dissociation rate. Under these conditions, even
GC in particular [23]. Since cholestyramine binds GC at the end of the dissociation period, the amount of GC
with weak affinity, and releases it rapidly, this perturba- bound per gram of polymer is comparable to the amount
tion should result in a decrease in the ability of a given of GDC bound.
dose of cholestyramine to bind bile acid over time, and Comparison with clinical results. These studies dem-
thus in reduced clinical efficacy. The experiment shown onstrate that sevelamer effectively binds bile acids in
in Figure 7 and described above was designed to mimic vitro, under a variety of conditions. The high binding
the time-dependent concentrations to which a seques- capacity and the favorable cooperative interactions
trant would be exposed as it traversed the gastrointes- among bile acids and fatty acids for binding to this poly-
tinal tract [26]. As shown in Figure 7, in the absence of mer suggest a significant potential as a bile acid seques-
fatty acid, there was a very rapid release of GC from trant. This potential may in turn explain the favorable
sevelamer. Hence, to the extent that GC release kinetics lipid lowering effects of sevelamer in hemodialysis pa-
tients and in healthy volunteers [1–3, 5–9].are dominant, our results suggest that sevelamer might
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